Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Milton S. Hershey Medical Center
Milton S. Hershey Medical Center
University of Virginia
Celgene
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics
National Cancer Institute (NCI)
Bristol-Myers Squibb
University of Iowa
Children's Oncology Group
University of Colorado, Denver
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Wake Forest University Health Sciences
University of Iowa
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)
Pediatric Brain Tumor Consortium
University of Iowa
Barbara Ann Karmanos Cancer Institute
Memorial Sloan Kettering Cancer Center
Stanford University
Wake Forest University Health Sciences
University of Louisville
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
University of South Florida
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Eli Lilly and Company